We report two ternary phase diagrams that show the synthesis conditions to prepare protein@ZIF biocomposites with different phases, including BSA@ZIF-C and insulin@ZIF-C. For each biocomposite, we measured distinct encapsulation efficiency and release profile properties.

Zeolitic imidazolate framework (ZIF) biocomposites show the capacity to protect and deliver biotherapeutics. To date, the progress in this research area is based on laboratory batch methods. Now, the first continuous flow synthetic method is presented for the encapsulation of a model protein (bovine serum albumin, BSA) and a clinical therapeutic (α1‐antitrypsin, AAT) in ZIF‐8. The in situ kinetics of nucleation, growth, and crystallization of BSA@ZIF‐8 were studied by small‐angle X‐ray scattering. By controlling the injection time of ethanol, the particle growth could be quenched by ethanol‐induced crystallization from amorphous particles to ZIF‐8 crystals. The particle size of the biocomposite was tuned in the 40–100 nm range by varying residence time prior to introduction of ethanol. As a proof‐of‐concept, this procedure was used for the encapsulation of AAT in ZIF‐8. Upon release of the biotherapeutic from the composite, the trypsin inhibitor function of AAT was preserved.

Gold nanoparticles (AuNPs) were anchored on alkynyl carbamate-functionalized support materials having the suitable features for application as catalysts in continuous-flow packed bed reactors. The functionalization step was carried out by grafting with the di-functional organosilane [3-(2-propynylcarbamate)propyl]triethoxysilane (PPTEOS) three commercial micrometer-sized oxide supports, i.e. silica, alumina, and titania. The alkynyl-carbamate moieties were capable to straightforwardly reduce the gold precursor HAuCl4 yielding the supported AuNPs systems Au/SiO2@Yne, Au/Al2O3@Yne, and Au/TiO2@Yne. A comparison among the three materials revealed that silica allowed the highest organic functionalization (12 wt%) as well as the highest gold loading (3.7 wt%). Moreover, TEM investigation showed only for Au/SiO2@Yne the presence of homogeneously distributed, spherically shaped AuNPs (av. diameter 15 nm). Au/SiO2@Yne is an efficient catalyst, both in batch and flow conditions, in the oxidation of a large variety of alcohols, using H2O2 as oxidizing agent, at a temperature of 90 °C. Furthermore, under flow conditions, the catalyst worked for over 50 h without any significant decrease in the catalytic activity. The catalytic activity of the three catalysts was evaluated and compared in the oxidation of 1-phenylethanol as a model substrate. We found that the flow approach plays a strategic role in preserving the physical and chemical integrity of the solid catalysts during its use, with remarkable consequences for the reaction conversion (from 2% in batch to 80 % in flow) in the case of Au/TiO2@Yne

Novel Ru–NHC complexes bearing cyclopentadienones/hydroxycyclopentadienyls are active and selective in transfer hydrogenation exploiting the cooperation of both classes of ligands.

Here we systematically varied the composition of the relative amounts of ligand (2-methylimidazole), metal precursor (Zn(OAc)2∙2H2O, and protein to prepare a series of protein@ZIF biocomposites. The effect of post synthetic treatments (i.e. washes with water or water/ethanol) was investigated. The XRD data of the examined samples were used to construct ternary diagrams. Five different phases were identified. The encapsulation efficiency (of bovine serum albumin and insulin) were phase dependent.

Zeolitic imidazolate framework (ZIF) biocomposites show the capacity to protect and deliver biotherapeutics. To date, the progress in this research area is based on laboratory batch methods. Now, the first continuous flow synthetic method is presented for the encapsulation of a model protein (bovine serum albumin, BSA) and a clinical therapeutic (α1‐antitrypsin, AAT) in ZIF‐8. The in situ kinetics of nucleation, growth, and crystallization of BSA@ZIF‐8 were studied by small‐angle X‐ray scattering. By controlling the injection time of ethanol, the particle growth could be quenched by ethanol‐induced crystallization from amorphous particles to ZIF‐8 crystals. The particle size of the biocomposite was tuned in the 40–100 nm range by varying residence time prior to introduction of ethanol. As a proof‐of‐concept, this procedure was used for the encapsulation of AAT in ZIF‐8. Upon release of the biotherapeutic from the composite, the trypsin inhibitor function of AAT was preserved.

No abstract

No abstract